Literature DB >> 17076451

Reference values for performance on the Automated Neuropsychological Assessment Metrics V3.0 in an active duty military sample.

Dennis L Reeves1, Joseph Bleiberg, Tresa Roebuck-Spencer, Alison N Cernich, Karen Schwab, Brian Ivins, Andres M Salazar, Sally C Harvey, Fred H Brown, Deborah Warden.   

Abstract

The Automated Neuropsychological Assessment Metrics (ANAM) is a computerized measure of processing speed, cognitive efficiency, and memory. This study describes performance and psychometric properties of ANAM in an active duty, healthy military sample (N = 2,371) composed primarily of young (18-46 years) adult males. Rarely have neuropsychological reference values for use with individuals in the military been derived from a large, active duty military population, and this is the first computerized neuropsychological test battery with military-specific reference values. Although these results do not provide demographically corrected, formal normative data, they provide reference points for neuropsychologists and other health care providers who are using ANAM data in research or clinical settings, with patients of comparable demographics to the present sample.

Entities:  

Mesh:

Year:  2006        PMID: 17076451     DOI: 10.7205/milmed.171.10.982

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  18 in total

1.  Cognitive disinhibition and infrequent moderate-to-intense physical activity linked with obesity in U.S. soldiers.

Authors:  Jennifer A Hanson; Gerit Wagner; Michael Dretsch
Journal:  Eat Weight Disord       Date:  2020-05-31       Impact factor: 4.652

2.  Inattention, impulsive action, and subjective response to D-amphetamine.

Authors:  Jessica Weafer; Harriet de Wit
Journal:  Drug Alcohol Depend       Date:  2013-06-18       Impact factor: 4.492

3.  Structural and Functional Integrity of the Intraparietal Sulcus in Moderate and Severe Traumatic Brain Injury.

Authors:  Chandler Sours; Prashant Raghavan; Alexandre E Medina; Steven Roys; Li Jiang; Jiachen Zhuo; Rao P Gullapalli
Journal:  J Neurotrauma       Date:  2017-02-27       Impact factor: 5.269

4.  Neurocognitive Function and Suicide in U.S. Army Soldiers.

Authors:  James A Naifeh; Matthew K Nock; Robert J Ursano; Patti L Vegella; Pablo A Aliaga; Carol S Fullerton; Ronald C Kessler; Christina L Wryter; Steven G Heeringa; Murray B Stein
Journal:  Suicide Life Threat Behav       Date:  2016-11-01

5.  Associations between interhemispheric functional connectivity and the Automated Neuropsychological Assessment Metrics (ANAM) in civilian mild TBI.

Authors:  Chandler Sours; Joseph Rosenberg; Robert Kane; Steve Roys; Jiachen Zhuo; Kathirkamanthan Shanmuganathan; Rao P Gullapalli
Journal:  Brain Imaging Behav       Date:  2015-06       Impact factor: 3.978

6.  Psychopharmacology of theobromine in healthy volunteers.

Authors:  Matthew J Baggott; Emma Childs; Amy B Hart; Eveline de Bruin; Abraham A Palmer; Joy E Wilkinson; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2013-02-19       Impact factor: 4.530

7.  Substance use and mental health characteristics associated with cognitive functioning among adults who use methamphetamine.

Authors:  Diane M Herbeck; Mary-Lynn Brecht
Journal:  J Addict Dis       Date:  2013

8.  Are attention lapses related to d-amphetamine liking?

Authors:  Michael McCloskey; Abraham A Palmer; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2009-11-21       Impact factor: 4.530

9.  Athlete characteristics and outcome scores for computerized neuropsychological assessment: a preliminary analysis.

Authors:  Cathleen N Brown; Kevin M Guskiewicz; Joseph Bleiberg
Journal:  J Athl Train       Date:  2007 Oct-Dec       Impact factor: 2.860

10.  Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests.

Authors:  John G Hanly; Antonina Omisade; Li Su; Vernon Farewell; John D Fisk
Journal:  Arthritis Rheum       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.